secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2024-12-30T23:59:59+00:00
Accession:  0001193125-24-286917
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept submits NDA for relacorilant to treat Cushing's syndrome
----------------------------------------------------------------

- NDA based on positive pivotal GRACE trial, Phase 3 GRADIENT, long-term extension and Phase 2 studies.
- No drug-induced adrenal insufficiency, hypokalemia, QT prolongation, or progesterone receptor effects seen.
- CEO Joseph Belanoff states relacorilant has potential to become standard of care for hypercortisolism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000119312524286917/0001193125-24-286917-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000119312524286917/d834253d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-286917

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer